Cardiology Stem Cells Market Report 2025

The cardiology stem cell market size has grown rapidly in recent years. It will grow from $1.69 billion in 2024 to $1.86 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to the rising incidence of cardiovascular diseases, increasing demand for regenerative therapies, the expansion of cardiac stem cell clinical trials, growing awareness of cell-based cardiac treatments, and improving success rates of early stem cell interventions.

The cardiology stem cell market size is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the rising adoption of personalized medicine, increasing government funding for regenerative therapies, the growing prevalence of chronic heart conditions, the expansion of stem cell manufacturing facilities, and a rise in approvals of cell-based cardiac treatments. Key trends anticipated during this period include advancements in cardiac tissue engineering, innovations in stem cell delivery methods, progress in gene-edited stem cells, research into 3D bioprinting for heart tissue, and the integration of artificial intelligence (AI) in the development of stem cell therapies.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the cardiology stem cell market in the coming years. Cardiovascular diseases include a range of disorders affecting the heart and blood vessels, such as coronary artery disease, stroke, hypertension, and heart failure. Their rising prevalence is largely attributed to aging populations, as older adults are more vulnerable to heart conditions, which in turn fuels demand for regenerative cardiac therapies. Cardiology stem cell therapy addresses these conditions by repairing and regenerating damaged heart tissue through multiple mechanisms. For example, in September 2024, the National Institutes of Health (NIH), a US-based government agency, projected that cardiovascular cases will nearly double between 2025 and 2050, with related deaths increasing from 20.5 million to 35.6 million. Consequently, the growing burden of cardiovascular diseases is boosting demand for cardiology stem cell treatments.

Companies in the cardiology stem cell market are developing advanced solutions such as integrated cardiac models to accelerate research and precision medicine innovations. Integrated cardiac models are frameworks that combine physiological, anatomical, and biochemical elements of the heart to simulate its function and behavior. For example, in January 2025, Ncardia BV, a Netherlands-based biotechnology company, introduced Ncyte Heart in a Box, a 3D cardiac microtissue system designed to improve drug discovery, disease modeling, and safety screening in cardiology. This platform incorporates high-purity hiPSC-derived cardiac cells into a functional microtissue format, providing improved translational relevance and predictive accuracy for therapeutic development. It supports applications in heart development studies, toxicity testing, and personalized medicine strategies.

In April 2022, Metcela Inc., a Japan-based clinical-stage biotechnology startup, acquired Regenerative Medicine Co. Ltd. (JRM) for an undisclosed amount. The acquisition was aimed at accelerating the development and commercialization of JRM-001, a cardiac stem cell therapy for pediatric congenital heart disease, while strengthening Metcela’s regenerative cardiology capabilities and expanding its therapeutic pipeline. Regenerative Medicine Co. Ltd. is a Japan-based company engaged in developing and researching cell-based therapies, including cardiology stem cell treatments.

Major players in the cardiology stem cells market are Pfizer Inc., Thermo Fisher Scientific Inc., Fujifilm Holdings Corporation, Baxter International Inc., Terumo Corporation, Evotec SE, Sana Biotechnology, Vericel Corporation, Takara Bio Inc., Orizuru Therapeutics Inc., Mesoblast Ltd., Athersys Inc., Pluri Inc., Longeveron Inc., Healios K.K, Celyad Oncology SA, Capricor Therapeutics Inc., BioCardia Inc., CardioCell, and StemCardia.

North America was the largest region in the cardiology stem cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiology stem cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiology stem cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Cardiology stem cells are specialized cells with the ability to self-renew and differentiate into various heart-related cell types, including muscle, vascular, and connective tissue cells. They possess the natural potential to support the repair and maintenance of cardiac structure by replacing cells that have been damaged or lost.

The key stem cell types used in cardiology include mesenchymal stem cells, induced pluripotent stem cells, embryonic stem cells, cardiac stem cells, adipose-derived stem cells, and bone marrow-derived stem cells. Mesenchymal stem cells, for example, are adult stem cells present in tissues such as bone marrow and fat. These therapies make use of a range of technologies, including conventional electric vaporization systems, advanced control platforms, smart vaporization devices, and energy-efficient vaporizers. Delivery methods vary and may involve intravenous, intracoronary, intramuscular, transendocardial, or direct surgical administration. Clinical applications include myocardial infarction, congestive heart failure, ischemic cardiomyopathy, post-surgical cardiac regeneration, arrhythmias and conduction disorders, as well as pediatric congenital heart diseases. The main end-users of these therapies are hospitals, research institutes, biotechnology companies, and related organizations.

The cardiology stem cells market research report is one of a series of new reports that provides cardiology stem cells market statistics, including cardiology stem cells industry global market size, regional shares, competitors with a cardiology stem cells market share, detailed cardiology stem cells market segments, market trends and opportunities, and any further data you may need to thrive in the cardiology stem cells industry. This cardiology stem cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiology stem cells market consists of revenues earned by entities by providing services such as stem cell sourcing and preparation, stem cell delivery, clinical trial management, patient assessment and monitoring, regenerative therapy consultation, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiology stem cell market also includes sales of cardiopoietic stem cells, stem cell-derived exosomes, stem cell cryopreservation kits, stem cell culture media, and stem cell isolation kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.